|
| related topics |
| {financial, litigation, operation} |
| {regulation, change, law} |
| {property, intellectual, protect} |
| {cost, regulation, environmental} |
| {personnel, key, retain} |
| {gas, price, oil} |
| {customer, product, revenue} |
| {acquisition, growth, future} |
| {competitive, industry, competition} |
| {system, service, information} |
| {operation, international, foreign} |
|
|
Competitive pressures could adversely affect the Company s results of operations and financial condition.
Substantial defaults or a material reduction in purchases of the Company s products by large customers could have an adverse effect on the Company s results of operations and financial condition.
Changes in the United States healthcare environment could adversely affect the Company s results of operations and financial condition.
The Company s Pharmaceutical Distribution business is subject to inflation in branded pharmaceutical prices and deflation in generic pharmaceutical prices, which subjects the Company to risks and uncertainties.
The ongoing SEC investigation and U.S. Attorney inquiry could adversely affect the Company s results of operations and financial condition.
The Company is subject to legal proceedings that could adversely affect the Company s results of operations, financial condition, liquidity and cash flows.
Additional restatements may be required, the historical consolidated financial statements may change or require amendment or additional disciplinary actions may be required.
Failure to comply with existing and future regulatory requirements could adversely affect the Company s results of operations and financial condition.
Circumstances associated with the Company s acquisition strategy could adversely affect the Company s results of operations and financial condition.
The Company could be adversely affected if transitions in senior management are not successful.
The Company s future results of operations are subject to fluctuations in the costs and availability of purchased components, compounds, raw materials and energy.
Proprietary technology protections may not be adequate.
The products that the Company manufactures or distributes may infringe on the intellectual property rights of third parties.
Risks generally associated with the Company s information systems could adversely affect the Company s results of operations.
Tax legislation initiatives or challenges to the Company s tax positions could adversely affect the Company s results of operations and financial condition.
The Company s global operations are subject to a number of economic, political and regulatory risks.
Full 10-K form ▸
|
|
| related documents |
| 12659--6/30/2008--H&R_BLOCK_INC |
| 25191--3/1/2006--COUNTRYWIDE_FINANCIAL_CORP |
| 1037949--2/8/2007--QWEST_COMMUNICATIONS_INTERNATIONAL_INC |
| 1037949--2/16/2006--QWEST_COMMUNICATIONS_INTERNATIONAL_INC |
| 96638--2/28/2007--ADVANTA_CORP |
| 1047202--6/13/2007--GETTY_IMAGES_INC |
| 68622--2/8/2007--QWEST_CORP |
| 68622--2/17/2006--QWEST_CORP |
| 83246--3/1/2010--HSBC_USA_INC_/MD/ |
| 943823--4/24/2008--DAVE_&_BUSTERS_INC |
| 30625--2/24/2010--FLOWSERVE_CORP |
| 1361658--2/19/2010--WYNDHAM_WORLDWIDE_CORP |
| 1018003--3/14/2006--INGRAM_MICRO_INC |
| 30625--2/25/2009--FLOWSERVE_CORP |
| 275053--3/20/2009--NATURES_SUNSHINE_PRODUCTS_INC |
| 275053--10/7/2008--NATURES_SUNSHINE_PRODUCTS_INC |
| 916459--2/29/2008--GARDNER_DENVER_INC |
| 275053--10/7/2008--NATURES_SUNSHINE_PRODUCTS_INC |
| 721371--8/24/2007--CARDINAL_HEALTH_INC |
| 1018003--3/2/2010--INGRAM_MICRO_INC |
| 1047202--2/29/2008--GETTY_IMAGES_INC |
| 1364742--3/13/2007--BlackRock_Inc. |
| 1124887--3/31/2009--CERIDIAN_CORP_/DE/ |
| 789073--3/1/2007--FORTUNE_BRANDS_INC |
| 891103--2/29/2008--IAC/INTERACTIVECORP |
| 1325814--3/14/2008--Federal_Home_Loan_Bank_of_Des_Moines |
| 786344--3/31/2006--GAINSCO_INC |
| 1039184--3/30/2010--TRAILER_BRIDGE_INC |
| 914536--2/23/2007--SPHERION_CORP |
| 914536--3/12/2008--SPHERION_CORP |
|